---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-23-000963"
form_type: "8-K"
ticker: null
cik: "0001497504"
company_name: "PLx Pharma Winddown Corp."
filed_at: "2023-07-07T23:59:59+00:00"
generated_at: "2026-06-13T11:00:26.619651+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# PLx Pharma Winddown terminates CEO and CFO amid Chapter 11 proceedings

## Summary
- Terminated CEO Natasha Giordano and CFO Rita O'Connor, effective June 30, 2023.
- CFO O'Connor entered consulting arrangement effective July 1, 2023.
- Board adopted bylaw amendment clarifying officer requirements on July 7, 2023.
- Company in Chapter 11 bankruptcy (Case No. 23-10456, District of Delaware).

## SEC filing metadata
- accession: 0001193805-23-000963
- form_type: 8-K
- cik: 0001497504
- company_name: PLx Pharma Winddown Corp.
- filed_at: 2023-07-07T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1497504/000119380523000963/0001193805-23-000963-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1497504/000119380523000963/e618763_8k-plx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-23-000963
- JSON: https://secwatch.observer/filing/0001193805-23-000963.json
- Plain text: https://secwatch.observer/filing/0001193805-23-000963.txt

## Key facts
- Executive change
  Natasha Giordano was terminated as President and Chief Executive Officer at PLx Pharma Winddown Corp..
  - Action: terminated
  - Role: President and Chief Executive Officer
  source text: In connection with the Chapter 11 Cases, on June 30, 2023, the Company terminated the employment of Natasha Giordano, President and Chief Executive Officer, and of Rita O’Connor, Chief Financial Officer and Head of Manufacturing and Supply Chain.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1497504/000119380523000963/0001193805-23-000963-index.htm
- Executive change
  Rita O’Connor was terminated as Chief Financial Officer and Head of Manufacturing and Supply Chain at PLx Pharma Winddown Corp..
  - Action: terminated
  - Role: Chief Financial Officer and Head of Manufacturing and Supply Chain
  source text: In connection with the Chapter 11 Cases, on June 30, 2023, the Company terminated the employment of Natasha Giordano, President and Chief Executive Officer, and of Rita O’Connor, Chief Financial Officer and Head of Manufacturing and Supply Chain.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1497504/000119380523000963/0001193805-23-000963-index.htm
- Governance Changes
  PLx Pharma Winddown Corp.: Amended Article 6 of the Bylaws to clarify officer requirements and make other clarifying changes (effective 2023-07-07).
  - Change: bylaw amendment
  - Effective: 2023-07-07
  source text: On July 7, 2023, the Board of Directors of the Company approved, and adopted effective as of such date, an amendment (the “Amendment”) to its Amended and Restated Bylaws (the “Bylaws”). The Amendment amends Article 6 of the Bylaws to clarify the requirements regarding officers of the Company and to make certain other clarifying changes.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1497504/000119380523000963/0001193805-23-000963-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.